Toward the Discovery and Development of PSMA Targeted Inhibitors for Nuclear Medicine Applications

Background: The rising incidence rate of prostate cancer (PCa) has promoted the development of new diagnostic and therapeutic radiopharmaceuticals during the last decades. Promising improvements have been achieved in clinical practice using prostate specific membrane antigen (PSMA) labeled agents, i...

Descripción completa

Detalles Bibliográficos
Autores principales: Pastorino, Sara, Riondato, Mattia, Uccelli, Licia, Giovacchini, Giampiero, Giovannini, Elisabetta, Duce, Valerio, Ciarmiello, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2020
Materias:
Current Radiopharmaceuticals
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509769/
https://www.ncbi.nlm.nih.gov/pubmed/31362683
http://dx.doi.org/10.2174/1874471012666190729151540

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509769/
https://www.ncbi.nlm.nih.gov/pubmed/31362683
http://dx.doi.org/10.2174/1874471012666190729151540

Ejemplares similares